Beaumont Health - Grosse Pointe
- Type
- Teaching hospital
- Where
- Grosse Pointe, MI
- Medicare CCN
- 230089
- Received
- $3,396,751 in 131 records, 2024 ($2,917,753 general, $478,997 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 52 | $2,917,753 |
| 2024 | Research payment | 79 | $478,997 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Royalty or License | 1 | $2,745,133 |
| Research payment | 79 | $478,997 |
| Long term medical supply or device loan | 6 | $68,054 |
| Space rental or facility fees (teaching hospital only) | 21 | $46,355 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 6 | $33,430 |
| Grant | 15 | $23,450 |
| Education | 1 | $1,250 |
| Debt forgiveness | 2 | $80 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,886 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,832 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,832 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $1,111 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $40 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $40 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-24 | United Therapeutics Corporation | $7,901 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,592 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $1,900 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-19 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-12-19 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2024 | |
| 2024-12-14 | SI-BONE, INC. | $10,500 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | PAULA | 2024 |
| 2024-12-09 | Medical Device Business Services, Inc. | $2,318 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-06 | Stryker Corporation | $11,417 | Research payment | Cash or cash equivalent | GAMMA Device, TRAUMA & EXTREMETIES | POST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-2022 | 2024 |
| 2024-12-02 | Janssen Research & Development, LLC | $15,552 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2024 | |
| 2024-12-02 | United Therapeutics Corporation | $9,896 | Research payment | Cash or cash equivalent | TYVASO Drug, Progressive Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2024 |
| 2024-11-28 | Ipsen Pharma SAS | $2,495 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-11-28 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-11-26 | United Therapeutics Corporation | $7,901 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-11-26 | UCB, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-21 | Ipsen Pharma SAS | $2,381 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-11-21 | Ipsen Pharma SAS | $1,190 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-11-15 | Providence Medical Technology, Inc. | $6,250 | Research payment | Cash or cash equivalent | Fuse Study | 2024 | |
| 2024-11-14 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | Device, General - Stents_IC | 2024 | |
| 2024-11-14 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | Device, General - Stents_IC | 2024 | |
| 2024-11-13 | UCB, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-11-12 | IRONWOOD PHARMACEUTICALS, INC | $22,142 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-11-09 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-11-01 | Providence Medical Technology, Inc. | $5,000 | Research payment | Cash or cash equivalent | Fuse Study | 2024 | |
| 2024-10-30 | United Therapeutics Corporation | $5,796 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-10-30 | United Therapeutics Corporation | $2,246 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-10-30 | Neurocrine BioSciences, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-10-25 | National Marrow Donor Program | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-10-17 | Novartis Pharmaceuticals Corporation | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-10-09 | United Therapeutics Corporation | $2,073 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-10-03 | Boston Scientific Corporation | $2,500 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-10-01 | Actelion Pharmaceuticals US, Inc. | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | UPTRAVI Drug, Cardiology | 2024 | |
| 2024-09-30 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-26 | Becton, Dickinson and Company | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-25 | United Therapeutics Corporation | $23,958 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-09-25 | United Therapeutics Corporation | $7,171 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-09-25 | United Therapeutics Corporation | $500 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-09-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | $28,275 | Research payment | Cash or cash equivalent | BI 1015550 - Ph3 Open Label Extension | 2024 | |
| 2024-09-19 | Barco, Inc. | $1,391 | Long term medical supply or device loan | In-kind items and services | 2024 | ||
| 2024-09-18 | Ipsen Pharma SAS | $2,912 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-18 | Ipsen Pharma SAS | $1,961 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-18 | Ipsen Pharma SAS | $1,303 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-18 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-18 | Neurelis, Inc. | $1,250 | Education | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2024 | |
| 2024-09-18 | Ipsen Pharma SAS | $1,190 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-09-17 | Novo Nordisk Inc | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-11 | Actelion Pharmaceuticals US, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPSUMIT Drug, Cardiology | 2024 | |
| 2024-08-26 | Ipsen Pharma SAS | $1,961 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-08-22 | IRONWOOD PHARMACEUTICALS, INC | $8,374 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-08-22 | Ipsen Pharma SAS | $2,732 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-08-22 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-08-22 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-08-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-08-08 | MOLNLYCKE HEALTH CARE US, LLC | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Mepilex Border Sacrum Device, Wound Care | 2024 | |
| 2024-08-01 | Janssen Research & Development, LLC | $250 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2024 | |
| 2024-07-31 | Ipsen Pharma SAS | $1,000 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-07-26 | National Marrow Donor Program | $615 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-07-19 | Roche TCRC, Inc. | $10,630 | Research payment | Cash or cash equivalent | Antibiotics MCP patient PK study | 2024 | |
| 2024-07-12 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-07-12 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $2,381 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $2,381 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $2,041 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $2,041 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-06-19 | Medical Device Business Services, Inc. | $21,000 | Research payment | Cash or cash equivalent | VIVIGEN MIS DELIVERY SYSTEM Device, Spine Trauma | Clinical Outcomes Associated with the use of ViviGen in Conjunction with Posterolateral Fusion for the Treatment of Lumb | 2024 |
| 2024-06-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-29 | Novo Nordisk Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-27 | Medical Device Business Services, Inc. | $804 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-22 | Elekta Limited | $58,350 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-05-20 | Elekta, Inc. | $2,745,133 | Royalty or License | Cash or cash equivalent | 2024 | ||
| 2024-05-13 | Medical Device Business Services, Inc. | $3,713 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-05-06 | Abbott Laboratories | $273 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2024 |
| 2024-05-03 | Boston Scientific Corporation | $5,000 | Grant | Cash or cash equivalent | Device, General - Therapies_EP | 2024 | |
| 2024-04-26 | National Marrow Donor Program | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-25 | IRONWOOD PHARMACEUTICALS, INC | $12,267 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-04-25 | Eli Lilly and Company | $1,807 | Research payment | In-kind items and services | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUN | 2024 | |
| 2024-04-22 | Medical Device Business Services, Inc. | $1,350 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-19 | Boston Scientific Corporation | $250 | Grant | In-kind items and services | Device, General - Therapies_EP | 2024 | |
| 2024-04-11 | Medical Device Business Services, Inc. | $1,350 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-11 | Medical Device Business Services, Inc. | $1,350 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-04-02 | Globus Medical, Inc. | $225 | Research payment | Cash or cash equivalent | Brigade Device, Spine/Spine Surgery | A prospective, multicenter study evaluating the safety and performance of interbody implants for the treatment of patien | 2024 |
| 2024-04-01 | Smith+Nephew, Inc. | $2,725 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2024 | |
| 2024-04-01 | Smith+Nephew, Inc. | $2,484 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2024 | |
| 2024-03-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-03-29 | Boston Scientific Corporation | $1,750 | Grant | In-kind items and services | Device, General - Therapies_PI | 2024 | |
| 2024-03-27 | MML US, Inc. | $300 | Research payment | Cash or cash equivalent | ReActiv8 Device, Pain Management | B Trial | 2024 |
| 2024-03-22 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-22 | Ipsen Pharma SAS | $1,274 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | $2,732 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | $2,732 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | $2,495 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-20 | Ipsen Pharma SAS | $1,168 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-03-15 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-03-11 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-03-11 | Medical Device Business Services, Inc. | $1,250 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-03-08 | Boston Scientific Corporation | $250 | Grant | In-kind items and services | Device, General - Therapies_EP | 2024 | |
| 2024-03-07 | Globus Medical, Inc. | $1,850 | Research payment | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat | 2024 |
| 2024-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $72,720 | Research payment | Cash or cash equivalent | PDE4 Phase III trial in IPF patients | 2024 | |
| 2024-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | $42,259 | Research payment | Cash or cash equivalent | PDE4 Phase III trial in PF-ILD | 2024 | |
| 2024-02-27 | IRONWOOD PHARMACEUTICALS, INC | $1,750 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-02-27 | IRONWOOD PHARMACEUTICALS, INC | $500 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-02-21 | Ipsen Pharma SAS | $1,190 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-02-15 | Globus Medical, Inc. | $2,325 | Research payment | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat | 2024 |
| 2024-02-15 | Globus Medical, Inc. | $500 | Research payment | Cash or cash equivalent | XLIF Device, Spine/Spine Surgery | NUVA.LIB1119: A prospective, multicenter study evaluating the safety and performance of interbody implants for the treat | 2024 |
| 2024-02-11 | Novartis Pharmaceuticals Corporation | $6,600 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENTRESTO Drug, Cardiology/Vascular Diseases | 2024 | |
| 2024-02-09 | SI-BONE, INC. | $1,650 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-02-07 | Smith+Nephew, Inc. | $2,725 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2024 | |
| 2024-02-07 | Smith+Nephew, Inc. | $2,484 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Q-FIX Device, Sports Med Shoulder | 2024 | |
| 2024-02-05 | Medical Device Business Services, Inc. | $500 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF Mediated Stroke 2 | 2024 | |
| 2024-02-02 | Boston Scientific Corporation | $400 | Grant | In-kind items and services | Device, General - Therapies_PI | 2024 | |
| 2024-02-01 | IRONWOOD PHARMACEUTICALS, INC | $3,831 | Research payment | Cash or cash equivalent | C3300-201 | 2024 | |
| 2024-01-29 | Eli Lilly and Company | $2,289 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI | 2024 | |
| 2024-01-29 | Abbott Laboratories | $740 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) | 2024 |
| 2024-01-12 | National Marrow Donor Program | $815 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-01-12 | SI-BONE, INC. | $600 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2024 |
| 2024-01-10 | Ipsen Pharma SAS | $2,912 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2024 |
| 2024-01-10 | Ipsen Pharma SAS | $2,142 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2024 |
| 2024-01-08 | Janssen Pharmaceuticals, Inc | $25,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2024 | |
| 2024-01-08 | Abbott Laboratories | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | XIENCE ALPINE Device, Vascular | 2024 | |
| 2024-01-05 | Boston Scientific Corporation | $1,500 | Grant | Cash or cash equivalent | Device, General - Catheter_IC | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Grosse Pointe, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Grosse Pointe, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 5,541 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 5,678 | 1,793,561 | 10,077,331 |
| Median age B01002 | 43.8 | 37.9 | 40.2 |
| Under 18 B01001 | 26.6% | 23.6% | 21.2% |
| 65 and over B01001 | 23.2% | 16.6% | 18.6% |
| Households B11001 | 2,211 | 700,591 | 4,076,369 |
| Foreign born B05002 | 7.8% | 10.3% | 7.2% |
| Median household income B19013 | $158,853 | $60,539 | $72,875 |
| Median family income B19113 | $180,357 | $79,522 | $93,357 |
| Per capita income B19301 | $86,088 | $34,906 | $40,735 |
| Poverty rate B17001 | 2.8% | 20.8% | 13.2% |
| Unemployment rate B23025 | 4.3% | 8.7% | 5.7% |
| Civilian labor force B23025 | 2,769 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.4 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 73.1% | 27.6% | 32.4% |
| Housing units B25001 | 2,452 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 85.9% | 64.8% | 73.2% |
| Renters B25003 | 14.1% | 35.2% | 26.8% |
| Median home value B25077 | $436,800 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,725 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 91.0% | 47.9% | 72.4% |
| Black B03002 | 1.5% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 3.1% | 6.9% | 5.9% |
| Asian B03002 | 1.0% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grosse Pointe, MI.
Comments